PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Inhibitors of BCL-X L , combined with inhibition of the mTOR/4E-BP axis, drive regressions of PIK3CA mutant breast tumors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Proliferation, cell cycle and apoptosis in cancer
Evan, G. I., & Vousden, K. H. (2001) · Nature · doi:10.1038/35077213 · Cited by 2,724 · cited 1×
“Growth signaling and cell cycle pathways have been pharmacologically targeted with some success, but the effectiveness of these strategies has been limited by incomplete and transient therapeutic responses (2, 3).”
BackgroundMolecular mechanisms of mTOR-mediated translational control
Ma, X. M., & Blenis, J. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2672 · Cited by 2,558
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992 · cited 1×
“For the case of BCL-2/BCLXL inhibitors, these doses are 5- to 12-fold lower than the equivalent doses required to cause dose-limiting thrombocytopenia in human and large animal models, which are important considerations given the dose-limiting toxicities observed in human clinical trials with these and related agents…”
BackgroundTargeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,900
Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
A unifying model for mTORC1-mediated regulation of mRNA translation
Thoreen, C. C., Chantranupong, L., Keys, H. R., Wang, T., Gray, N. S., & Sabatini, D. M. (2012) · Nature · doi:10.1038/nature11083 · Cited by 1,477
Certo, M., Moore, V. D. G., Nishino, M., Wei, G., Korsmeyer, S., Armstrong, S. A., & Letai, A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.027 · Cited by 1,288 · cited 1×
“There has been a focused effort in the past decade to develop small-molecule inhibitors of the B cell lymphoma–2 (BCL-2) family proteins [such as BCL–extra large (BCL-XL), BCL-2, and myeloid cell leukemia–1 (MCL-1)]—the key antiapoptotic proteins in the mitochondria—on the basis of the observation that some cancer cel…”
BackgroundHuman breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells
Elenbaas, B., Spirio, L., Koerner, F., Fleming, M. D., Zimonjic, D. B., Donaher, J. L., Popescu, N. C., Hahn, W. C., & Weinberg, R. A. (2001) · Genes & Development · doi:10.1101/gad.828901 · Cited by 878
Roberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S. Z., Huang, D. C. S., Xiong, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7898 · Cited by 830
Development of PI3K inhibitors: lessons learned from early clinical trials
Rodon, J., Dienstmann, R., Serra, V., & Tabernero, J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.10 · Cited by 766
Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
Pan, R., Hogdal, L. J., Benito, J. M., Bucci, D., Han, L., Borthakur, G., Cortes, J., DeAngelo, D. J., Debose, L., Mu, H., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0609 · Cited by 735
ROCK Inhibitor and Feeder Cells Induce the Conditional Reprogramming of Epithelial Cells
Liu, X., Ory, V., Chapman, S., Yuan, H., Albanese, C., Kallakury, B., Timofeeva, O. A., Nealon, C., Dakic, A., Simic, V., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.10.036 · Cited by 726
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Hata, A. N., Engelman, J. A., & Faber, A. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0011 · Cited by 619
Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy
Chonghaile, T. N., Sarosiek, K. A., Vo, T.-T., Ryan, J. A., Tammareddi, A., Moore, V. D. G., Deng, J., Anderson, K. C., Richardson, P., Tai, Y.-T., et al. (2011) · Science · doi:10.1126/science.1206727 · Cited by 585
Diagnosing and exploiting cancer's addiction to blocks in apoptosis
Letai, A. G. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2297 · Cited by 580 · cited 2×
“Cell-intrinsic apoptosis is a tightly regulated process that is controlled by the balance of pro- and antiapoptotic proteins in the mitochondria (6, 7).”
BackgroundFernald, K., & Kurokawa, M. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.07.006 · Cited by 579 · cited 4×
“One such class of agents that may be useful for priming solid tumors to create synthetic lethal dependencies on BCL-2 family proteins are phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway inhibitors (15).”
BackgroundInfluentialObligate Role of Anti-Apoptotic MCL-1 in the Survival of Hematopoietic Stem Cells
Opferman, J. T., Iwasaki, H., Ong, C. C., Suh, H., Mizuno, S.-I., Akashi, K., & Korsmeyer, S. J. (2005) · Science · doi:10.1126/science.1106114 · Cited by 574 · cited 1×
“Furthermore, there are currently no bioavailable inhibitors that have been demonsrated to target MCL-1 in humans, and a body of literature suggests that such agents may be difficult to tolerate owing to MCL-1’s physiological essentiality, its role in hematopoietic stem cell survival, and its potential roles outside of…”
BackgroundLeverson, J. D., Phillips, D. C., Mitten, M. J., Boghaert, E. R., Diaz, D., Tahir, S. K., Belmont, L. D., Nimmer, P., Xiao, Y., Ma, X. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4642 · Cited by 541
Mcl‐1; the molecular regulation of protein function
Thomas, L. W., Lam, C., & Edwards, S. W. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.05.061 · Cited by 538 · cited 1×
“is regulated independently of this axis inPIK3CAWTbreast cancers, suggesting that alternative regulators of the eIF4F complex may be relevant therapeutic targets in this context (15, 33, 46).”
BackgroundTumours with PI3K activation are resistant to dietary restriction
Kalaany, N. Y., & Sabatini, D. M. (2009) · Nature · doi:10.1038/nature07782 · Cited by 468
Leverson, J. D., Zhang, H., Chen, J., Tahir, S. K., Phillips, D. C., Xue, J., Nimmer, P., Jin, S., Smith, M., Xiao, Y., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.561 · Cited by 440
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors
Vora, S. R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E. L., Pollack, S. F., Liu, M., Li, X., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.020 · Cited by 438 · cited 1×
“This finding also adds to a body of recent literature describing approaches to sensitize PIK3CAmutant breast cancers to PI3K/mTOR pathway inhibitors, for example, by using cyclin-dependent kinase 4 (CDK4)/ CDK6 inhibitors or by targeting multiple nodes within the pathway (44, 45).”
Mcl-1 deficiency results in peri-implantation embryonic lethality
Rinkenberger, J. L., Horning, S., Klocke, B., Roth, K., & Korsmeyer, S. J. (2000) · Genes & Development · doi:10.1101/gad.14.1.23 · Cited by 397 · cited 1×
“Furthermore, there are currently no bioavailable inhibitors that have been demonsrated to target MCL-1 in humans, and a body of literature suggests that such agents may be difficult to tolerate owing to MCL-1’s physiological essentiality, its role in hematopoietic stem cell survival, and its potential roles outside of…”
BackgroundInhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
Muranen, T., Selfors, L. M., Worster, D. T., Iwanicki, M. P., Song, L., Morales, F. C., Gao, S., Mills, G. B., & Brugge, J. S. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.024 · Cited by 384
Corcoran, R. B., Cheng, K. A., Hata, A. N., Faber, A. C., Ebi, H., Coffee, E. M., Greninger, P., Brown, R. D., Godfrey, J. T., Cohoon, T. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.007 · Cited by 377
Targeting the eIF4F Translation Initiation Complex: A Critical Nexus for Cancer Development
Pelletier, J., Graff, J., Ruggero, D., & Sonenberg, N. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2789 · Cited by 367
Genome-scale loss-of-function screening with a lentiviral RNAi library
Root, D. E., Hacohen, N., Hahn, W. C., Lander, E. S., & Sabatini, D. M. (2006) · Nature Methods · doi:10.1038/nmeth924 · Cited by 357
Elkabets, M., Vora, S., Juric, D., Morse, N., Mino-Kenudson, M., Muranen, T., Tao, J., Campos, A. B., Rodon, J., Ibrahim, Y. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005747 · Cited by 332
Placzek, W. J., Wei, J., Kitada, S., Zhai, D., Reed, J. C., & Pellecchia, M. (2010) · Cell Death & Disease · doi:10.1038/cddis.2010.18 · Cited by 294
mTOR inhibitors in cancer therapy
Zaytseva, Y. Y., Valentino, J. D., Gulhati, P., & Mark Evers, B. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.005 · Cited by 291
mTORC1 promotes survival through translational control of Mcl-1
Mills, J. R., Hippo, Y., Robert, F., Chen, S. M. H., Malina, A., Lin, C.-J., Trojahn, U., Wendel, H.-G., Charest, A., Bronson, R. T., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804821105 · Cited by 285
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors
Faber, A. C., Corcoran, R. B., Ebi, H., Sequist, L. V., Waltman, B. A., Chung, E., Incio, J., Digumarthy, S. R., Pollack, S. F., Song, Y., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0106 · Cited by 283
Current treatment strategies for inhibiting mTOR in cancer
Chiarini, F., Evangelisti, C., McCubrey, J. A., & Martelli, A. M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.11.004 · Cited by 275 · cited 1×
“Finally, given that BEZ235’s clinical development has been halted because of poor pharmacokinetics and toxicity and that its activity in PIK3CA mutant cells can be phenocopied using ATP-competitive mTOR inhibitors like MLN-0128 and AZD2014 that are currently in clinical development for the treatment of breast cancer,…”
BackgroundChonghaile, T. N., Roderick, J. E., Glenfield, C., Ryan, J., Sallan, S. E., Silverman, L. B., Loh, M. L., Hunger, S. P., Wood, B., DeAngelo, D. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0353 · Cited by 275 · cited 1×
“Although most cell lines derived from solid tumorswere insensitive toABT737 [growth inhibition of 50% (GI50) > 1 mM], a reference pair of acute myeloid leukemia cell lines previously reported to be sensitive to BCL-2 inhibition (HL60 and MOLM13) was sensitive to this drug (GI50 < 1 mM) (19).”
BackgroundSarosiek, K. A., Chi, X., Bachman, J. A., Sims, J. J., Montero, J., Patel, L., Flanagan, A., Andrews, D. W., Sorger, P., & Letai, A. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.08.048 · Cited by 247
Sutherland, R. L., Green, M. D., Hall, R. E., Reddel, R. R., & Taylor, I. W. (1983) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(83)90177-3 · Cited by 209
Systematic identification of signaling pathways with potential to confer anticancer drug resistance
Martz, C. A., Ottina, K. A., Singleton, K. R., Jasper, J. S., Wardell, S. E., Peraza-Penton, A., Anderson, G. R., Winter, P. S., Wang, T., Alley, H. M., et al. (2014) · Science Signaling · doi:10.1126/scisignal.aaa1877 · Cited by 191
Self-citationTreatment of triple negative breast cancer (TNBC): current options and future perspectives
De Laurentiis, M., Cianniello, D., Caputo, R., Stanzione, B., Arpino, G., Cinieri, S., Lorusso, V., & De Placido, S. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70025-6 · Cited by 184
Targeting Apoptosis Pathways for New Cancer Therapeutics
Bai, L., & Wang, S. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-010713-141310 · Cited by 176
Mechanisms of Acquired Resistance to Targeted Cancer Therapies
Lackner, M. R., Wilson, T. R., & Settleman, J. (2012) · Future Oncology · doi:10.2217/fon.12.86 · Cited by 164
Walsh, D., Perez, C., Notary, J., & Mohr, I. (2005) · Journal of Virology · doi:10.1128/jvi.79.13.8057-8064.2005 · Cited by 131 · cited 1×
“Consistent with previous studies demonstrating multiple levels of eIF4F regulation, these results demonstrate that capdependent MCL-1 translation is rate-limited by mTOR/4E-BP activity in PIK3CA mutant cells, but that in WT cells, it is limited by other aspects of eIF4F complex regulation, suggesting that future studi…”
BackgroundFaber, A. C., Farago, A. F., Costa, C., Dastur, A., Gomez-Caraballo, M., Robbins, R., Wagner, B. L., Rideout, W. M., Jakubik, C. T., Ham, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411848112 · Cited by 127
Faber, A. C., Coffee, E. M., Costa, C., Dastur, A., Ebi, H., Hata, A. N., Yeo, A. T., Edelman, E. J., Song, Y., Tam, A. T., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0315 · Cited by 124
Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer
Goodwin, C. M., Rossanese, O. W., Olejniczak, E. T., & Fesik, S. W. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.73 · Cited by 118
Gores, G. J., & Kaufmann, S. H. (2012) · Genes & Development · doi:10.1101/gad.186189.111 · Cited by 107
Jebahi, A., Villedieu, M., Pétigny-Lechartier, C., Brotin, É., Louis, M.-H., Abeilard, E., Giffard, F., Guercio, M., Briand, M., Gauduchon, P., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.03.001 · Cited by 66
Markou, A. N., Farkona, S., Schiza, C., Efstathiou, T., Kounelis, S., Malamos, N., Georgoulias, V., & Lianidou, E. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0149 · Cited by 61
Histological and Molecular Evaluation of Patient-Derived Colorectal Cancer Explants
Uronis, J. M., Osada, T., McCall, S. J., Yang, X. Y., Mantyh, C. R., Morse, M. A., Lyerly, H. K., Clary, B. M., & Hsu, D. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038422 · Cited by 55
Self-citationMicroSCALE Screening Reveals Genetic Modifiers of Therapeutic Response in Melanoma
Wood, K. C., Konieczkowski, D. J., Johannessen, C. M., Boehm, J. S., Tamayo, P., Botvinnik, O. B., Mesirov, J. P., Hahn, W. C., Root, D. E., Garraway, L. A., et al. (2012) · Science Signaling · doi:10.1126/scisignal.2002612 · Cited by 36
Self-citationTargeting the Regulatory Machinery of BIM for Cancer Therapy
Harada, H., & Grant, S. (2012) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v22.i2.40 · Cited by 34 · cited 1×
“Cell-intrinsic apoptosis is a tightly regulated process that is controlled by the balance of pro- and antiapoptotic proteins in the mitochondria (6, 7).”
BackgroundThe BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells
Baev, D. V., Krawczyk, J., O'Dwyer, M. E., & Szegezdi, É. (2014) · Leukemia Research Reports · doi:10.1016/j.lrr.2014.06.001 · Cited by 22
Massacesi, C., di Tomaso, E., Urban, P., Germa, C., Fretault, N., Dharan, B., Tavorath, R., Quadt, C., Coughlin, C. M., & Hirawat, S. (2015) · The Journal of OncoPathology · doi:10.13032/tjop.2052-5931.100107 · Cited by 4
Cited by
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Labrie, M., Brugge, J. S., Mills, G. B., & Zervantonakis, I. K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00454-5 · Cited by 369
Fan, F., Liu, P., Bao, R., Chen, J., Zhou, M., Mo, Z., Ma, Y., Liu, H., Zhou, Y., Cai, X., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1547 · Cited by 198
“However, clinical experience has indicated that targeting a single oncoprotein is often not sufficient to achieve desired therapeutic efficacy due to the development of resistance either by functional redundancy of alternative pathways or genetic mutations that enable drug resistance in surviving cancer cells (9, 10).”
BackgroundMerino, D., Whittle, J. R., Vaillant, F., Serrano, A., Gong, J.-N., Giner, G., Maragno, A. L., Chanrion, M., Schneider, E., Pal, B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7049 · Cited by 185
Protein translation: biological processes and therapeutic strategies for human diseases
Jia, X., He, X., Huang, C., Li, J., Dong, Z., & Liu, K. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01749-9 · Cited by 185
“134,135 Relatedly, in colorectal cancer, alterations in translation factors, including increased expression levels of eIFs, contribute to enhanced protein synthesis and upregulation of key factors involved in cell proliferation, tumor growth, metastasis, and oxaliplatin resistance.”
BackgroundDysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors
Anderson, G. R., Wardell, S. E., Çakır, M., Yip, C., Ahn, Y.-R., Ali, M., Yllanes, A. P., Chao, C., McDonnell, D. P., & Wood, K. C. (2018) · Nature Communications · doi:10.1038/s41467-018-04033-x · Cited by 146
Self-citation
Metadata
- Authors
- Anderson, G. R., Wardell, S. E., Cakir, M., Crawford, L., Leeds, J. C., Nussbaum, D. P., Shankar, P. S., Soderquist, R. S., Stein, E. M., Tingley, J. P., Winter, P. S., Zieser-Misenheimer, E. K., Alley, H. M., Yllanes, A., Haney, V., Blackwell, K. L., McCall, S. J., McDonnell, D. P., & Wood, K. C.
- Affiliations
- Department of Pharmacology and Cancer Biology, Duke University, Durham, NC 27710, USA.
- Duke University (US)
- Corresponding author
- Wood, Kris C.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-12-14
- Volume
- 8
- Issue
- 369
- Pages
- 369ra175-369ra175
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5626456
- OpenAlex
- W2563571637
- Cited by
- 53
- References
- 57
- Citations by year
- 2025: 4 · 2024: 5 · 2023: 4 · 2022: 10 · 2021: 7 · 2020: 4 · 2019: 7 · 2018: 10 · 2017: 2
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- DukeSpace (Duke University) (submittedVersion, cc-by-nc-nd)
- Funders
- Duke University School of Medicine
- Duke Cancer Institute
- NIH Building Interdisciplinary Research Careers in Women’s Health Program (K12HD043446)
- Golfers Against Cancer Research Award
- Stewart Trust Fellowship
- NSF (DGE-1106401, DGF-1106401)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- PIK3CA mutation, breast cancer, mTOR signaling, 4E-BP, Bcl-xL inhibitors, tumor dependency, combination therapy, PI3K/Akt signaling
- MeSH terms
- Animals, Breast Neoplasms, DNA Mutational Analysis, Female, Humans, Mice, Nude, Mutation, Neoplasm Transplantation, Gene Expression Regulation, Neoplastic, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Combinatorial Chemistry Techniques, MAP Kinase Signaling System, Cell Line, Tumor, bcl-X Protein, Mice, Class I Phosphatidylinositol 3-Kinases, TOR Serine-Threonine Kinases, Molecular Targeted Therapy, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.